精准治疗时代下广泛期小细胞肺癌联合治疗研究进展OA
Advances in Systemic Therapy for Extensive-stage Small Cell Lung Cancer in the Era of Precision Treatment
广泛期小细胞肺癌(extensive-stage small cell lung cancer,ES-SCLC)进展迅速、复发率高、预后较差,仍是肺癌治疗领域的难点.近年来,免疫检查点抑制剂联合依托泊苷含铂化疗成为ES-SCLC的一线治疗标准,推动ES-SCLC由传统化疗向多模式联合及精准分层转变,为疗效突破带来新的机遇和挑战.本文基于临床治疗路径,从标准化方案、维持策略、临床局限性及前沿研究热点等方面,综述了ES-SCLC的化疗、免疫、靶向、放疗、中医药等多学科联合治疗研究进展,以期在精准治疗时代为ES-SCLC的个体化治疗与全程管理提供参考.
Extensive-stage small cell lung cancer(ES-SCLC)is characterized by rapid progression,a high risk of recurrence,and poor prognosis,and remains a major therapeutic challenge in lung cancer.In recent years,immune checkpoint inhibitors combined with Platinum-Etoposide chemotherapy have become the standard first-line treatment for ES-SCLC,driving a shift from conventional chemotherapy toward multimodal combination strategies and precision-guided patient stratification,while creating both new opportunities and challenges for further therapeutic improvement.Following the clinical treatment pathway,this review summarizes advances in multidisciplinary combination treatment for ES-SCLC,including chemotherapy,immunotherapy,targeted therapy,radiotherapy,and traditional Chinese medi-cine,with emphasis on standard regimens,maintenance therapy,clinical limitations,and emerging research directions.This review aimed to provide a reference for individualized treatment and comprehensive disease management of ES-SCLC in the era of precision medicine.
陈涵芮;徐俪雯;程奕暄;周蕾
200032 上海,上海中医药大学附属龙华医学院200032 上海,上海中医药大学附属龙华医学院200032 上海,上海中医药大学附属龙华医学院200032 上海,上海中医药大学附属龙华医学院
肺肿瘤小细胞肺癌免疫疗法免疫检查点抑制剂抗血管生成靶向治疗放疗中医药精准医学
Lung neoplasmsSmall cell lung cancerImmunotherapyImmune checkpoint inhibitorsAngiogen-esis inhibitorsTargeted therapyRadiotherapyTraditional Chinese medicinePrecision medicine
《中国肺癌杂志》 2026 (7)
500-508,9
This paper was supported by the grants from the National Project for Advancing Key Specialized Clinics in Traditional Chinese Medicine(Traditional Chinese Medicine Oncology)(No.XH40202-202509040,to Hegen LI),National Project for High-level Key Disciplines in Traditional Chinese Medicine(Oncology),Ministry of Traditional Chinese Medicine(No.zyyzdxk-2023063,to Hegen LI),National Medical Center Clinical Research Project(No.GFB2401-1-1,to Lei ZHOU),Long-hua Hospital of Shanghai University of Traditional Chinese Medicine Shanghai New Three-Year Action Plan Research Project(No.GFB2502,to Lei ZHOU)and Health Commission of Pudong New Area,Shanghai Municipality,Joint Research Project(No.PW2024D-13,to Lei ZHOU). 本文受国家中医优势专科建设项目(中医肿瘤)(No.XH40202-202509040)、国家中医药管理局高水平中医药重点学科建设项目(中医肿瘤病学)(No.zyyzdxk-2023063)、上海中医药大学龙华医院国家医学中心临床研究项目(No.GFB2401-1-1)、上海市新三年行动计划研究项目(No.GFB2502)和上海市浦东新区卫生健康委员会联合攻关项目(No.PW2024D-13)资助
评论